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http://dx.doi.org/10.1016/j.bbmt.20for multiple reasons are no longer appropriate candidates for
curative therapy with allogeneic transplantation. As I write
this commentary here at this year’s American Society of
Hematology meeting, I am struck by the vibrant communityAs specialists in applying the procedure of allogeneic
immunotherapy for the treatment of various diseases, we
often struggle with “getting our timing right.” As noted by
Joshua Harris, “The right thing at the wrong time is the
wrong thing.” Thus, in this issue of Biology of Blood and
Marrow Transplantation,Warlick et al. [1] highlight a topic of
great interest. In what setting are patients who enter non-
myeloablative allogeneic transplant “optimized” for long-
term outcome? Do we consider the potential logarithmic
cell kill provided by pretransplant consolidation, with po-
tential to minimize residual disease, as outweighing the risk
of additional damage done to the adult body exposed to
repeated cycles of chemotherapy, especially regarding he-
patic, nutritional, and infectious concerns in recovery from
transplantation?
This issue has been addressed in the alternative setting
of ablative therapy by multiple retrospective reviews, and
in those circumstances adding more consolidation beyond
the point of attaining morphologic remission does not
appear to impact outcomes [2,3]. Given the added in-
tensity of the myelosuppressive and concomitant anti-
tumor beneﬁt of the ablative preparations used, the
impact of consolidation in the less than ablative setting
remains unclear. In this issue, Warlick et al. present a large
retrospective analysis of the effect of postremission
cytarabine consolidation therapy on the outcome of
transplantation for patients with acute myeloid leukemia.
Six hundred four patients reported to the Center for
International Bone Marrow Transplant Research over a
10-year period who received reduced-intensity or non-
myeloablative therapy from a matched related or unre-
lated donor or unrelated cord blood donor were included
in the analysis. Notably, 3-year overall and disease survival
rates were not signiﬁcantly different, nor were relapse
rates.
This is important information for our logistical concerns
in allogeneic immunotherapy. When the transplant team
ﬁrst consults on patients only after all prior therapy decisions
have been completed, we often bemoan the fact that patients
do not come to our attention until they are “over-treated” orrequests: David Rizzieri, Professor of
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10.
m.duke.edu
2014 American Society for Blood and
13.12.556of both young and more experienced thought leaders
focused on the care of such patients, yet many are aware of
the disappointing data concerning care patterns in our
country. Review of information from the Surveillance,
Epidemiology, and End Results program indicates poor sur-
vival in older acute myeloid leukemia patients as often a self-
fulﬁlling prophecy, because only one third of patients over
age 65 years diagnosed from 2000 to 2007were even offered
chemotherapy [4]. The authors noted that at each age in-
terval, chemotherapy-treated patients lived longer than
those who did not receive therapy. Further, only .8% of such
patients were offered an allogeneic stem cell transplant.
Similarly, Estey et al. [5] noted that only one half of patients
over age 50 years who would have been eligible for a
transplant were even referred for consultation. Warlick et al.
indicate 604 patients were transplanted with a matched
donor or cord blood in the last decade; thus, one of the big
questions left for us to address is this:Where did all the other
patients go?
This work highlights the potential value of integrating
our treatment algorithms from initial diagnosis through
consolidation plans and ensuring patients are being treated
by “leukemia teams.” Because proceeding with trans-
plantation as soon as remission is obtained provides
equivalent outcomes, we can minimize unnecessary
chemotherapy exposures with efﬁcient care planning. At the
point of diagnosis, a thorough initial cytogenetics and mo-
lecular analysis must be done. Based on these results, the
patient’s risk for long-term disease control with standard
therapies versus transplantation can be clariﬁed and, if
transplant is a reasonable option, ensure donor searches are
begun, ﬁnancial support veriﬁed, and patient education
initiated.
Progress is being made in this regard. Data from the
Center for International Bone Marrow Transplant Research
suggest that transplants in the elderly are on the rise, as
the percentage of patients over the age of 50 undergoing
allogeneic transplant has nearly doubled in the last decade,
in part due to the advent of newer preparative regimens, as
noted by Warlick and colleagues [6]. The new intergroup
study, “A Randomized Phase III Study of Standard Cytar-
abine plus Daunorubicin (7þ3) Therapy or Idarubicin with
High Dose Cytarabine (IA) Versus IA with Vorinostat (NSC-
701852) (IAþV) in Younger Patients with Previously Un-
treated Acute Myeloid Leukemia (AML) (NSC-701852),”
addresses this issue of integrated care directly as the rate
of success in having newly diagnosed patients under age
60 years referred for a consultation with the transplant
team is an important secondary objective of the study. This
J.H. Antin / Biol Blood Marrow Transplant 20 (2014) 145e148146study will allow us to address some of the limitations of
the current review based on the transplant population:
What are the complete set of reasons patients known to be
at higher risk do not proceed to transplant? How many
patients attain a remission though relapse early and before
a donor is prepared? What role might persistence of
minimal residual disease have in the outcome of the cho-
sen treatments?
Thus, Warlick et al. provide important information for the
current issue of optimizing our timing of transplantation,
noting that with current standard induction therapy, there is
beneﬁt in either situation of early or delayed transplant,
conﬁrming an adage made popular by Willie Nelson, “The
early bird gets the worm, but the second mouse gets the
cheese.” Of course, as therapies evolve away from traditional
approaches, we will need to continually reassess the value of
consolidation after less intense or targeted therapies as well,
ensuring repeated analyses of this type should be considered
in the future.Financial disclosure: See Acknowledgments on page 147.
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there may be disease-speciﬁc differences, conditioning-
speciﬁc differences, or infection-related differences. On
this background we try to interpret each new provocativeWe have made undeniable progress in the application
of hematopoietic stem cell transplantation (HSCT) to a
variety of malignant and nonmalignant diseases. Patients
are older and have more comorbidities, most problems
with HLA compatibility are manageable, and supportive
care techniques have made the management of infections,
veno-occlusive disease, and other transplant-related tox-
icities much more tractable. And yet, improving the pre-
vention and treatment of graft-versus-host disease (GVHD)
remains a challenge. No wonder that any apparent inno-
vation that appears to be effective generates a great deal of
interest.
Our ﬁeld is littered with phase II studies of “promising”
agents and approaches that have failed to live up to their
promise in phase III studies [1-3]. A substantial problem
that we have dealt with poorly is the substantial hetero-
geneity of the patients to whom these innovations are
applied. Children may not respond the same way as adults;
GVHD after umbilical cord blood transplantation may bestudy.
There are a number of important caveats in analyzing
data involving patients with severe GVHD. With severe
GVHD of the gastrointestinal tract and complete loss of the
absorptive epithelium, even in the context of a perfectly
effective immunosuppressive therapy, at what pace do we
anticipate clinical improvement? Three days? One week?
One month? If the diarrhea improves in a few days, do we
ascribe beneﬁt to the new agent or was it a late response to
the previous therapy? The liver is even more problematic.
Few of us would advocate serial liver biopsies to assess the
response to an investigational therapy. With biopsy-proven
loss of biliary canaliculi, at what pace do we anticipate
normalization of the bilirubin? What if the bilirubin never
normalizes? Does that mean there is ongoing inﬂammation
or does it mean there is irreversible injury to small biliary
radicles?
The deﬁnition of steroid-refractory is critical as well. If we
decide after 3 days of methylprednisolone that steroids have
failed and enroll the patient in a phase II trial of a novel
agent, how do we interpret responses that occur in the next
week or even 2 weeks? Is this just the normal time course of
response to the initial therapy, that is, the time it takes for the
mucosa to regenerate, or is it a true response to the drug?
I suspect that many “promising” drugs fail in phase III trials
because the interpretation of response data was overly
optimistic.
